<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02234804</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-111-13</org_study_id>
    <nct_id>NCT02234804</nct_id>
  </id_info>
  <brief_title>The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study</brief_title>
  <acronym>DOCTOR Recross</acronym>
  <official_title>The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, controlled, double randomized, non-blinded, multicenter, investigator initiated,
      academic superiority trial comparing optical coherence tomography (OCT) guided vs.
      angiography guided wire recrossing in jailed side branches (SB) (1. randomization
      1:1)(superiority) and comparing Medtronic Resolute Integrity and Xience Prime for stent strut
      apposition in the SB ostium (2. randomization 1:1) (superiority). Acute primary endpoint and
      30 days clinical follow-up.

      Hypothesis: OCT guided wire recrossing in bifurcation stenting results in less malapposed
      struts in the segment facing the SB ostium.

      Secondary hypothesis: Treatment by Medtronic Resolute Integrity stent results in less
      malapposed struts at the bifurcation segment compared to treatment by the Abbott Xience Prime
      stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      To assess the ability of OCT to guide wire recrossing and reduce stent strut malapposition
      after kissing balloon dilatation.

      To compare stent strut apposition after treatment by two different stent designs using both
      guiding strategies of wire recrossing.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cross sectional stent strut malapposition in the main vessel bifurcation segment facing the side-branch ostium compared for optical coherence tomography and angioguided recrossing strategy</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural: 1. Success in recrossing into designated strut hole when visible and indicated</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural: 2. Procedure duration (sheath insertion to closure device excluding treatment of other vessels)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural: 3. Contrast use</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural: 4. Fluoroscopy time</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoints: 5. Malapposition in the main vessel segment limited by and facing the side-branch ostium compared for stent type (second randomization)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoints: Malapposition in the proximal and distal main vessel segments and in the quadrants opposite to the side branch origin for stent type and recross strategy</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoints: Distance between malapposed strut and vessel wall in all segments for stent type and recross strategy</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoints: Minimum expansion of the stents expressed as absolute area and percentage of the closest reference area, for stent type and recross strategy</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoints: Ostial stent area stenosis by optical coherence tomography (side branch reference area by 3D QCA)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoints: Segmental assessment; Proximal edge, proximal main vessel, bifurcation segment, distal main vessel, distal edge, ostial 5 mm of side branch. Pre and post side branch intervention</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ostial side branch area stenosis</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ostial side branch acute gain after main vessel (MV) stenting</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal luminal area of all segments</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic area stenosis of all other segments</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Medtronic Resolute Integrity stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Angiography to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience Prime stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience Prime Stent</intervention_name>
    <arm_group_label>OCT</arm_group_label>
    <arm_group_label>Angiography</arm_group_label>
    <other_name>Stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Resolute Integrity stent</intervention_name>
    <arm_group_label>OCT</arm_group_label>
    <arm_group_label>Angiography</arm_group_label>
    <other_name>Stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiography</intervention_name>
    <arm_group_label>Medtronic Resolute Integrity stent</arm_group_label>
    <arm_group_label>Xience Prime stent</arm_group_label>
    <other_name>CAG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>OCT</intervention_name>
    <arm_group_label>Medtronic Resolute Integrity stent</arm_group_label>
    <arm_group_label>Xience Prime stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable or unstable angina pectoris or silent angina pectoris.

          -  De novo coronary bifurcation lesions at &quot;LAD/diagonal&quot;, &quot;Cx/obtuse marginal&quot;, &quot;right
             coronary artery (RCA)- posterior descending artery (PDA)/posterolateral branch&quot; or
             &quot;left main (LM)/Cx/LAD&quot;.

          -  All Medina classes except Medina 0.0.1.

          -  Diameter of side branch ≥2.5 mm.

          -  Diameter stenosis &gt;50% by operator's visual assessment

          -  Signed informed consent

        Exclusion Criteria:

          -  ST-elevation infarction within 48 hours.

          -  Side branch lesion length &gt;5 mm.

          -  Expected survival &lt; 1 year

          -  Severe heart failure (NYHA≥III)

          -  S-creatinine &gt;120 µmol/l.

          -  Allergy to Contrast media, Aspirin, Clopidogrel, Ticagrelor, Ticlopidine, Everolimus
             or Zotarolimus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels R Holm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital Skejby</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niels R Holm, MD</last_name>
    <phone>+45 7845 0000</phone>
    <phone_ext>52254</phone_ext>
    <email>niels.holm@ki.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evald H Christiansen, MD</last_name>
    <phone>+45 7845 0000</phone>
    <phone_ext>52028</phone_ext>
    <email>hellbarg@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Adriaenssens, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tom Adriasenssens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hspital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels R Holm, MD</last_name>
      <phone>+45 7845 0000</phone>
      <phone_ext>52254</phone_ext>
      <email>niels.holm@clin.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Evald H Christiansen, MD</last_name>
      <phone>+45 7845 0000</phone>
      <phone_ext>52028</phone_ext>
      <email>hellbarg@rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Niels R Holm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo DiMario, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carlo DiMario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2014</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Niels Ramsing Holm</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Coronary angiography (CAG)</keyword>
  <keyword>Percutaneous coronary intervention (PCI)</keyword>
  <keyword>OCT</keyword>
  <keyword>Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

